TommyBoyTrader

[lucky__stock]

$USAQ USA Equities Corp. Reports Fourth Quarter and Full Year 2021 Financial Results
Fourth Quarter 2021 Revenue Up 265%

?

Revenue Surpassed $1.4 million for the year ended 2021 Compared to $124,000 for 2020

?

Gross Margin of 52% in Q4 Increased 1,200 Basis Points Versus Q4 2020

?

Strong balance sheet growth during 2021 with $2.2M in assets including the AllergiEnd® asset acquisition

?

Pending FINRA approval to change the Company’s Name to QHSLab, Inc.

West Palm Beach, FL, April 05, 2022 (GLOBE NEWSWIRE) -- USA Equities Corp (OTCQB: USAQ), a digital healthcare company focused on providing clinicians with artificial intelligence tools to leverage proactive, value-based healthcare solutions through the use of emerging digital and point of care technologies, announced its financial results for the fourth quarter and full-year 2021.

“The $1.6 million acquisition of the AllergiEnd® assets in June 2021 has created a robust strategic platform to build upon in 2022 and beyond. The revenue generated from AllergiEnd® product sales was $329,989 in the fourth quarter of 2021 compared to $124,532 for the same period in 2020 and $1,414,421 for the year 2021 compared to $124,532 for 2020. In addition, our physician practice clients generated approximately $5,000,000 in revenues utilizing our products during 2021. This is a huge benefit to our physician clients especially in this current climate of decreasing reimbursements for primary care physicians,” said USAQ CEO Troy Grogan.

“During 2021, 163 medical practices provided 11,235 patients with our allergy diagnostic tests generating approximately $3.8 million in new reimbursements for these practices. Additionally, physicians at these 163 practices provided our allergen immunotherapy treatments to 1,019 patients generating approximately $1.2 million in new reimbursements for our customers. Traditionally, general practice physicians would have elected not to treat these conditions or referred the patients to an allergy specialist. It is estimated that practices utilizing AllergiEnd® and QHSLab enjoyed an additional 5-10% income for their practices with the addition of the Company’s products and treatments. Few of these 163 practices were utilizing the Company’s products at the beginning of 2021 as many became customers during the year, so in many cases, on a rolling 12 months basis, the Company’s products and services may be enabling these practices to achieve increased income levels well above 10% compared to not using the Company’s platform, products and services.” concluded Grogan.

https://finance.yahoo.com/news/usa-equities-corp-reports-fourth-120000501.html